Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial
Zsolt Horváth, Michele Ghidini, Iwona Danielewicz, Joleen M. Hubbard et al.
Citations
4 citations
Journal
JNCI Cancer Spectrum
Topics
Neutropenia and Cancer Infections
Field-Weighted Citation Impact (FWCI)
1.13
article
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial
Zsolt Horváth, Michele Ghidini, Iwona Danielewicz, Joleen M. Hubbard, Igor Bondarenko, Matti Aapro, Andrew P. Beelen, Heinz‐Josef Lenz, Robert H. Jones, Emerson Y. Chen, Jennifer Adeleye, Wayne Wang, Pilar García‐Alfonso, Tianshu Liu, Jufeng Wang, Yanqiao Zhang
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
JNCI Cancer SpectrumVol. 9(1)
Institutions
University of Southern California (US), Universidad Complutense de Madrid (ES), Abbott Northwestern Hospital (US), Allina Health (US), Harbin Medical University (CN), Oregon Health & Science University (US), Fudan University (CN), Velindre NHS Trust (GB), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Hospital General Universitario Gregorio Marañón (ES), Zhengzhou University (CN), Triangle (US), Third Affiliated Hospital of Harbin Medical University (CN), Clinique de Genolier (CH), Bács-Kiskun Megyei Kórház (HU), Zhongshan Hospital (CN), Henan Cancer Hospital (CN), G1 Therapeutics (United States) (US), Cardiff University (GB), Dnipro State Medical University (UA)